Health Condition 1: E08-E13- Diabetes mellitus Health Condition 2: I20-I25- Ischemic heart diseases
Conditions
Interventions
Control Intervention1: NIL: NIL
Control Intervention2: T. Prasugrel: 60 mg loading dose (pre PCI) followed by 10 mg once daily maintenance dose
Control Intervention3: T. Ticagrelor: 180 mg loading dos
Sponsors
Dr Ankita Panigrahy
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients aged between 35 - 70 years of either gender. 2.Diabetic patients , with either stable angina, unstable angina or NSTEMI, with the above mentioned drug therapy and planned for PCI. 3.Patients with Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 after PCI.
Exclusion criteria
Exclusion criteria: 1. Patients posted for Coronary bypass surgery. 2. Patients with uncontrolled diabetes 3. History of stroke or transient ischemic attack or intracranial bleeding at any time 4. Patients who had previous cardiac intervention 5. Patients with cardiogenic shock or hypovolemia 6. Left Ventricular Ejection Fraction (LVEF) 7. Patients with ST segment elevated myocardial infarction 8. Patients with chronic kidney disease stage 3 and beyond 9. Patients requiring reintervention in the study period 10. Need for chronic anti coagulation therapy 11. Patients whose liver function test values are more than 2 times the upper limit of normal 12. History of gastrointestinal bleeding within past 6 months 13. Hypersensitivity to study drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in levels of hsCRP, IL-6,TNF-alpha after 3 months of treatment compared to baseline Safety of the drugsTimepoint: baseline, 4 weeks, 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety- any incidence of bleeding or stent thrombosisTimepoint: 1 month,4 months | — |
Countries
India
Contacts
Public ContactDr Ankita Panigrahy
Nizams institute of medical sciences, Hyderabad
Outcome results
None listed